ACTG 219--PEDIATRIC LATE OUTCOMES PROTOCOL

ACTG 219--儿科晚期结果方案

• 批准号: 6274981
• 负责人: FRANK GIGLIOTTI
• 金额: $ 1.96万
• 依托单位: UNIVERSITY OF ROCHESTER
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6274981
• 关键词: AIDS therapy; HIV infections; antiAIDS agent; antiviral agents; child physical development; child psychology; clinical research; drug screening /evaluation; human subject; human therapy evaluation; infant human (0-1 year); long term survivor; longitudinal human study; neurologic manifestations; neuropharmacology; neuropsychological tests; outcomes research; pediatric AIDS; quality of life

Prospective, longitudinal data collection for late outcomes and late treatment effects of antietroviral therapy in uninfected infants. The purpose of this study is to follow children who are currently enrolled in or were previously enrolled in pediatric ACTG treatment or drug research studies to look for any late consequences of therapy in growth, neurologic and neuropsychologic function long-term survival and quality of life. Children will be followed until their 21st birthday.

前瞻性、纵向数据收集，用于晚期结局和晚期 抗病毒治疗对未感染婴儿的治疗效果。 的 这项研究的目的是跟踪目前参加的儿童， 或之前参加过儿童ACTG治疗或药物研究 研究寻找治疗对生长、神经系统 和神经心理功能的长期生存和生活质量。 孩子们将被跟踪到21岁生日。